Skip to main content

Anogenital Warts

2
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Leo Pharma
Leo PharmaDenmark - Ballerup
1 program
1
PicatoPhase 21 trial
Active Trials
NCT02377999Completed40Est. Nov 2015
Medigene
MedigeneGermany - Planegg-Martinsried
1 program
1
VeregenPhase 11 trial
Active Trials
NCT01490008Completed30Est. Mar 2012
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
The Role of Genital Warts in HIV Acquisition in PeruN/A1 trial
Active Trials
NCT01387412Completed600Est. Sep 2015
Vaxart
VaxartSOUTH SAN FRANCISCO, CA
1 program
AP611074PHASE_1_21 trial
Active Trials
NCT01532102Completed24Est. May 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Leo PharmaPicato
VaxartAP611074
MedigeneVeregen
Angeles TherapeuticsThe Role of Genital Warts in HIV Acquisition in Peru

Clinical Trials (4)

Total enrollment: 694 patients across 4 trials

NCT02377999Leo PharmaPicato

Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

Start: Feb 2015Est. completion: Nov 201540 patients
Phase 2Completed
NCT01532102VaxartAP611074

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

Start: Feb 2012Est. completion: May 201324 patients
Phase 1/2Completed
NCT01490008MedigeneVeregen

Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers

Start: Dec 2011Est. completion: Mar 201230 patients
Phase 1Completed
NCT01387412Angeles TherapeuticsThe Role of Genital Warts in HIV Acquisition in Peru

The Role of Genital Warts in HIV Acquisition in Peru

Start: Apr 2012Est. completion: Sep 2015600 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.